NCT00936871View on ClinicalTrials.gov

The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Healthy Volunteers

Interventions

DRUG

Lersivirine

Lersivirine 2400 mg single dose

DRUG

Placebo

Placebo single dose

DRUG

Lersivirine (if necessary)

Lersivirine 2100 mg single dose (if necessary)

DRUG

Lersivirine

Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)

DRUG

Placebo

Placebo single dose

DRUG

Moxifloxacin

Moxifloxacin 400 mg single dose

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT00936871 - The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects | Biotech Hunter | Biotech Hunter